What if billion-dollar women’s health markets were still being dismissed as “optional”?
From contraception to vaginal and sexual health, these needs are universal, recurring, and clinically significant. Yet too many investors see them as lifestyle choices rather than core medical priorities.
In this episode of Blindspot Capital, I sit down with Sabrina Johnson, President & CEO of Daré Bioscience, to unpack the misconceptions keeping capital on the sidelines and why disciplined science could be the key to unlocking this market.
We talk scientific credibility, market opportunity, and why angel investors have a unique leadership role to play in women’s health.
Watch now to learn why medicine is not marketing and why the distinction matters when building solutions that can change millions of lives.
🎧 Watch full episode on YouTube
About Daré Bioscience:
Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch.
The company’s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Learn more here.
Share this post